MEDMIX AG |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 15.09 CHF | -0.85% |
|
-1.56% | -20.53% |
| Apr. 17 | AARDEX Group announced that it has received funding from medmix AG | CI |
| Apr. 16 | Medmix Unit Enters Japanese Distribution Deal for PiccoJect Product | MT |
| Sales 2024 * | 521M 570M | Sales 2025 * | 563M 616M | Capitalization | 621M 680M |
|---|---|---|---|---|---|
| Net income 2024 * | 34M 37.23M | Net income 2025 * | 51M 55.84M | EV / Sales 2024 * | 1.5 x |
| Net Debt 2024 * | 160M 176M | Net Debt 2025 * | 109M 119M | EV / Sales 2025 * | 1.3 x |
| P/E ratio 2024 * |
18.3
x | P/E ratio 2025 * |
12.1
x | Employees | 2,658 |
| Yield 2024 * |
4.93% | Yield 2025 * |
5.42% | Free-Float | 58.12% |
More Fundamentals
* Assessed data
More news
Latest transcript on medmix AG
More press releases
| 1 day | -0.85% | ||
| 1 week | -1.56% | ||
| Current month | -5.74% | ||
| 1 month | -4.43% | ||
| 3 months | -12.62% | ||
| 6 months | -20.19% | ||
| Current year | -20.53% |
1 week
15.00
15.86
1 month
14.8016.58
Current year
14.4018.96
1 year
14.4026.75
3 years
14.4048.44
5 years
14.4048.44
10 years
14.4048.44
| Managers | Title | Age | Since |
|---|---|---|---|
Girts Cimermans
CEO | Chief Executive Officer | 54 | 21-09-19 |
Jennifer Dean
DFI | Director of Finance/CFO | 56 | 21-09-19 |
Alan Richardson
COO | Chief Operating Officer | 53 | 23-02-28 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
David Metzger
BRD | Director/Board Member | 54 | 22-04-11 |
| Chairman | 64 | 22-04-11 | |
Marco Musetti
BRD | Director/Board Member | 55 | 21-09-19 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.01% | 773 M€ | -.--% | - | |
| 0.00% | 10 M€ | -3.35% | - | |
| 0.00% | 34 M€ | +2.67% | - | |
| 0.00% | 29 M€ | -3.48% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-29 | 15.1 | -0.79% | 5 635 |
| 24-04-26 | 15.22 | -2.06% | 41,439 |
| 24-04-25 | 15.54 | +0.13% | 39,772 |
| 24-04-24 | 15.52 | +1.04% | 62,857 |
| 24-04-23 | 15.36 | +0.13% | 22,532 |
Delayed Quote Swiss Exchange, April 29, 2024 at 09:25 am EDT
More quotes
Medmix Systems AG is a Switzerland-based company active in manufacturing of high-precision delivery devices. The Company operates in business areas such as: the dental segment, which provides MIXPAC and transcodent - system solutions that are used to dose, mix and apply various types of dental materials; drug delivery- solutions for the dosage and application of drugs; a surgical segment which provides devices for bone regeneration and tissue healing; an industry segment that specializes in the mixing and dosing of sealants and adhesives through IXPAC , COX and MK; and a beauty segment in which it produces cosmetic applicators through the GEKA brand.
Calendar
2024-07-17
- Q2 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
15.22
CHF
Average target price
30
CHF
Spread / Average Target
+97.11%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -20.53% | 679M | |
| -1.94% | 187B | |
| -2.56% | 106B | |
| -3.97% | 66.9B | |
| +2.56% | 49.45B | |
| +16.88% | 48B | |
| +4.06% | 40.84B | |
| +3.10% | 26.48B | |
| +2.39% | 26.25B | |
| +12.96% | 24.62B |
- Stock Market
- Equities
- MEDX Stock
